Evidence map›Paper›PMID 29399943›Full record

ArticleAging cell2018

High-throughput serum proteomics for the identification of protein biomarkers of mortality in older men.

Eric S Orwoll, Jack Wiedrick, Jon Jacobs, Erin S Baker, Paul Piehowski, Vladislav Petyuk, Yuqian Gao, Tujin Shi, Richard D Smith, Douglas C Bauer and 4 more

Erratum issuedAbstract read
In one paragraph

Article in Aging cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Proteomic Markers of Aging and Longevity: A Systematic Review.International journal of molecular sciences · 2024
    Pooled it
  2. SAA4: An Underdog Within the Serum Amyloid a Superfamily?International journal of molecular sciences · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Cross-platform proteomics signatures of extreme old age.bioRxiv : the preprint server for biology · 2024
    Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Eric S OrwollOregon Health & Science University, Portland, OR, USA.ORCID 0000-0002-8520-7355
Jack WiedrickOregon Health & Science University, Portland, OR, USA.
Jon JacobsBiological Science Division, Pacific Northwest National Laboratory, Richland, WA, USA.
Erin S BakerBiological Science Division, Pacific Northwest National Laboratory, Richland, WA, USA.
Paul PiehowskiBiological Science Division, Pacific Northwest National Laboratory, Richland, WA, USA.
Vladislav PetyukBiological Science Division, Pacific Northwest National Laboratory, Richland, WA, USA.
Yuqian GaoBiological Science Division, Pacific Northwest National Laboratory, Richland, WA, USA.
Tujin ShiBiological Science Division, Pacific Northwest National Laboratory, Richland, WA, USA.
Richard D SmithBiological Science Division, Pacific Northwest National Laboratory, Richland, WA, USA.
Douglas C BauerDepartment of Medicine, University of California, San Francisco, CA, USA.
Steven R CummingsCalifornia Pacific Medical Center Research Institute, San Francisco, CA, USA.
Carrie M NielsonOregon Health & Science University, Portland, OR, USA.ORCID 0000-0002-2619-7839
Jodi LapidusOregon Health & Science University, Portland, OR, USA.
Osteoporotic Fractures in Men Study (MrOS) Research Group

Funding

Oregon Clinical and Translational Research Institute - The National COVID Cohort Collaborative (N3C)UL1TR002369 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI Cynthia D Morris, Christopher G. Slatore · 2017 to 2026
$78.4M
OREGON CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024140 · NCRR · OREGON HEALTH & SCIENCE UNIVERSITY · PI ORWOLL, ERIC S. · 2006 to 2011
$61.1M
Oregon Clinical and Translational Research InstituteUL1TR000128 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI ELLISON, DAVID H · 2012 to 2015
$28.7M
Equipment Supplement Request for a Research Resource for Ultra-sensitive High Throughput ProteomicsP41GM103493 · NIGMS · BATTELLE PACIFIC NORTHWEST LABORATORIES · PI PAYNE, SAMUEL H · 2012 to 2022
$22.6M
OSTEOPOROTIC FRACTURES IN MENU01AG018197 · NIA · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI CUMMINGS, STEVEN RON · 1999 to 2011
$12.7M
Osteoporotic Fractures in Men (MrOS) - San Francisco Coordinating CenterU01AR066160 · NIAMS · CALIFORNIA PACIFIC MED CTR RES INSTITUTE · PI CUMMINGS, STEVEN RON · 2013 to 2017
$9.3M
Osteoporotic Fractures in Men: MrOS Renewal-PortlandU01AR045647 · NIAMS · OREGON HEALTH & SCIENCE UNIVERSITY · PI ORWOLL, ERIC S. · 1999 to 2011
$6.7M
Sex Differences in response to an exercise for hyperkyphosisP50AR063043 · NIAMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI KATZMAN, WENDY BETH · 2012 to 2017
$5.7M
Osteporotic Fractures in Men (MrOS)- Admin CenterU01AG027810 · NIA · OREGON HEALTH & SCIENCE UNIVERSITY · PI ORWOLL, ERIC S. · 2006 to 2017
$5.1M
Osteoporotic Fractures in Men - Renewal: PittsburghU01AR045654 · NIAMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CAULEY, JANE ANN · 1999 to 2011
$5.1M
OSTEOPOROTIC FRACTURES IN MENU01AR045614 · NIAMS · UNIVERSITY OF MINNESOTA TWIN CITIES · PI ENSRUD, KRISTINE · 1999 to 2011
$4.0M
Osteoporotic Fractures in MenU01AR045583 · NIAMS · STANFORD UNIVERSITY · PI STEFANICK, MARCIA L. · 1999 to 2011
$4.0M
NCATS NIH HHS UL1 TR000128NCATS NIH HHS UL1 TR002369NCRR NIH HHS UL1 RR024140NIAMS NIH HHS K01 AR062655NIAMS NIH HHS P50 AR063043NIAMS NIH HHS U01 AR045580NIAMS NIH HHS U01 AR045583NIAMS NIH HHS U01 AR045614NIAMS NIH HHS U01 AR045632NIAMS NIH HHS U01 AR045647NIAMS NIH HHS U01 AR045654NIAMS NIH HHS U01 AR066160NIA NIH HHS U01 AG018197NIA NIH HHS U01 AG027810NIA NIH HHS U01 AG042124NIGMS NIH HHS P41 GM103493
6 · The paper itself

Abstract

The biological perturbations associated with incident mortality are not well elucidated, and there are limited biomarkers for the prediction of mortality. We used a novel high-throughput proteomics approach to identify serum peptides and proteins associated with 5-year mortality in community-dwelling men age ≥65 years who participated in a longitudinal observational study of musculoskeletal aging (Osteoporotic Fractures in Men: MrOS). In a discovery phase, serum specimens collected at baseline in 2473 men were analyzed using liquid chromatography-ion mobility-mass spectrometry, and incident mortality in the subsequent 5 years was ascertained by tri-annual questionnaire. Rigorous statistical methods were utilized to identify 56 peptides (31 proteins) that were associated with 5-year mortality. In an independent replication phase, selected reaction monitoring was used to examine 21 of those peptides in baseline serum from 750 additional men; 81% of those peptides remained significantly associated with mortality. Mortality-associated proteins included a variety involved in inflammation or complement activation; several have been previously linked to mortality (e.g., C-reactive protein, alpha 1-antichymotrypsin) and others are not previously known to be associated with mortality. Other novel proteins of interest included pregnancy-associated plasma protein, VE-cadherin, leucine-rich α-2 glycoprotein 1, vinculin, vitronectin, mast/stem cell growth factor receptor, and Saa4. A panel of peptides improved the predictive value of a commonly used clinical predictor of mortality. Overall, these results suggest that complex inflammatory pathways, and proteins in other pathways, are linked to 5-year mortality risk. This work may serve to identify novel biomarkers for near-term mortality.

Indexed as

BiomarkersHumansMaleMortalityProteomicsBiomarkersagingbiomarkerinflammationmenmortalityproteomics

Identifiers

PMID29399943
PMCPMC5847880

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.